{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:38:54Z","timestamp":1783413534746,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40273-021-01059-w","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T04:45:50Z","timestamp":1625114750000},"page":"901-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4874-0334","authenticated-orcid":false,"given":"Kate","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-0180","authenticated-orcid":false,"given":"Daniel","family":"Aggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-9943","authenticated-orcid":false,"given":"Peter","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8257-1151","authenticated-orcid":false,"given":"Katerina","family":"Anokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew J.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-4781","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"issue":"10095","key":"1059_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(17)30062-4.","journal-title":"Lancet"},{"key":"1059_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295\u2013305. https:\/\/doi.org\/10.2147\/CLEP.S245642.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"1059_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/cjn.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey M-A, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362. https:\/\/doi.org\/10.2215\/cjn.04760512.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1059_CR4","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/cjn.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844\u201359. https:\/\/doi.org\/10.2215\/cjn.02210310.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1059_CR5","unstructured":"European Medicines Agency. Eculizumab (Soliris). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf. Accessed 1 Jun 2021."},{"key":"1059_CR6","unstructured":"US Food and Drug Administration. Eculizumab (Soliris). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125166s434lbl.pdf. Accessed 1 Jun 2021."},{"issue":"23","key":"1059_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New Engl J Med. 2013;368(23):2169\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1208981.","journal-title":"New Engl J Med."},{"issue":"5","key":"1059_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061\u201373. https:\/\/doi.org\/10.1038\/ki.2014.423.","journal-title":"Kidney Int"},{"issue":"1","key":"1059_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1059_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701\u201311. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026.","journal-title":"Kidney Int"},{"issue":"11","key":"1059_CR11","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep. 2019;4(11):1568\u201376. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.016.","journal-title":"Kidney Int Rep."},{"issue":"5","key":"1059_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00467-019-4192-7","volume":"34","author":"G Ariceta","year":"2019","unstructured":"Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS): a question to be addressed in a scientific way. Pediatr Nephrol. 2019;34(5):943\u20139. https:\/\/doi.org\/10.1007\/s00467-019-4192-7.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1059_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","volume":"55","author":"F Fakhouri","year":"2018","unstructured":"Fakhouri F, Loirat C. Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol. 2018;55(3):150\u20138. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.04.009.","journal-title":"Semin Hematol"},{"key":"1059_CR14","unstructured":"US Food and Drug Administration. Ravulizumab (Ultomiris). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761108s005lbl.pdf. Accessed 1 Jun 2021."},{"key":"1059_CR15","unstructured":"European Medicines Agency. Ravulizumab (Ultomiris). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf. Accessed 1 Jun 2021."},{"key":"1059_CR16","unstructured":"Alexion Pharmaceuticals Inc. Ultomiris\u00ae (ravulizumab) receives approval in Japan for atypical hemolytic uremic syndrome (aHUS) in adults and children. 2020. https:\/\/ir.alexion.com\/news-releases\/news-release-details\/ultomirisr-ravulizumab-receives-approval-japan-atypical. Accessed 1 Jun 2021."},{"issue":"4","key":"1059_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4): e0195909. https:\/\/doi.org\/10.1371\/journal.pone.0195909.","journal-title":"PLoS ONE"},{"issue":"6","key":"1059_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035.","journal-title":"Kidney Int"},{"key":"1059_CR19","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00467-019-04325-4","volume":"34","author":"LA Greenbaum","year":"2019","unstructured":"Greenbaum LA, Adams B, Cheong HI, Constantinescu ER, Denker AE, Dixon BP, et al. The long-acting complement inhibitor ravulizumab in children with atypical haemolytic uraemic syndrome (interim analysis). Pediatr Nephrol. 2019;34:1821\u20132260. https:\/\/doi.org\/10.1007\/s00467-019-04325-4.","journal-title":"Pediatr Nephrol"},{"key":"1059_CR20","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","volume":"23","author":"Y Wang","year":"2020","unstructured":"Wang Y, Johnston K, Popoff E, Myren K-J, Cheung A, Faria C, et al. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. J Med Econ. 2020;23:1503\u201315. https:\/\/doi.org\/10.1080\/13696998.2020.1831519.","journal-title":"J Med Econ"},{"key":"1059_CR21","doi-asserted-by":"publisher","first-page":"S841","DOI":"10.1016\/j.jval.2019.09.2337","volume":"22","author":"A Levy","year":"2019","unstructured":"Levy A, Chen PGF, Tomazos I. Comparing productivity losses from treating atypical hemolytic uremic syndrome patients in the United States with eculizumab or ravulizumab in an infusion clinic or at home. Value Health. 2019;22:S841. https:\/\/doi.org\/10.1016\/j.jval.2019.09.2337.","journal-title":"Value Health."},{"issue":"1","key":"1059_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7\u201322. https:\/\/doi.org\/10.1002\/hec.3564.","journal-title":"Health Econ"},{"issue":"1","key":"1059_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"FR Johnson","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health."},{"issue":"27","key":"1059_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. Morb Mortal Wkly Rep. 2017;66(27):734\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm6627e1.","journal-title":"Morb Mortal Wkly Rep"},{"key":"1059_CR25","unstructured":"Sloane NJA. A library of orthogonal arrays. http:\/\/neilsloane.com\/oadir\/. Accessed 1 Jun 2021."},{"key":"1059_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/9780470148563","volume-title":"The construction of optimal stated choice experiments: theory and methods. Wiley series in probability and statistics","author":"DJ Street","year":"2007","unstructured":"Street DJ, Burgess L. The construction of optimal stated choice experiments: theory and methods. Wiley series in probability and statistics. Hoboken: Wiley; 2007."},{"key":"1059_CR27","unstructured":"Statistics Canada. Census program. 2016. https:\/\/www12.statcan.gc.ca\/census-recensement\/index-eng.cfm?MM=1. Accessed 1 Jun 2021."},{"key":"1059_CR28","unstructured":"Australian Bureau of Statistics. Census. 2016. https:\/\/www.abs.gov.au\/census. Accessed 1 Jun 2021."},{"key":"1059_CR29","unstructured":"Office for National Statistics. Census. 2011. https:\/\/www.ons.gov.uk\/. Accessed 1 Jun 2021."},{"key":"1059_CR30","unstructured":"Centraal Bureau voor de Statistiek. StatLine. 2020. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/en\/. Accessed 26 Nov 2020."},{"key":"1059_CR31","unstructured":"SCB Statistika Centralbyr\u00e5n. Finding statistics. 2020. https:\/\/www.scb.se\/en\/finding-statistics\/. Accessed 1 Jun 2021."},{"issue":"1","key":"1059_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12955-018-0857-3","volume":"16","author":"H Dakin","year":"2018","unstructured":"Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31. https:\/\/doi.org\/10.1186\/s12955-018-0857-3.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1059_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1536867X0700700306","volume":"7","author":"AR Hole","year":"2007","unstructured":"Hole AR. Fitting mixed logit models by using maximum simulated likelihood. Stata J. 2007;7(3):388\u2013401. https:\/\/doi.org\/10.1177\/1536867X0700700306.","journal-title":"Stata J"},{"key":"1059_CR34","unstructured":"Australian Government Actuary. Australian life tables 2015\u201317. 2019. https:\/\/aga.gov.au\/publications\/life-tables\/australian-life-tables-2015-17. Accessed 1 Jun 2021."},{"key":"1059_CR35","unstructured":"Statistics Canada. Life expectancy at various ages, by population group and sex, Canada. 2020. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310013401. Accessed 1 Jun 2021."},{"key":"1059_CR36","unstructured":"World Health Organization. Global Health Observatory data repository: life tables by country: Netherlands. 2016. https:\/\/apps.who.int\/gho\/data\/?theme=main&vid=61160. Accessed 1 Jun 2021."},{"key":"1059_CR37","unstructured":"World Health Organization. Global Health Observatory data repository: life tables by country: Sweden. 2016. https:\/\/apps.who.int\/gho\/data\/view.main.61600?lang=en. Accessed 26 Nov 2020."},{"key":"1059_CR38","unstructured":"Office for National Statistics. National life tables, UK: 2014 to 2016. 2017. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2014to2016. Accessed 1 Jun 2021."},{"key":"1059_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1477-7525-10-139","volume":"10","author":"L Neri","year":"2012","unstructured":"Neri L, McEwan P, Sennf\u00e4lt K, Baboolal K. Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study. Health Qual Life Outcomes. 2012;10:139. https:\/\/doi.org\/10.1186\/1477-7525-10-139.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1059_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40273-019-00862-w","volume":"38","author":"M Ryan","year":"2020","unstructured":"Ryan M, Donato BMK, Irish W, Gasteyger C, L\u2019Italien G, Laurence J. Economic impact of early-in-hospital diagnosis and initiation of eculizumab in atypical haemolytic uraemic syndrome. Pharmacoeconomics. 2020;38(3):307\u201313. https:\/\/doi.org\/10.1007\/s40273-019-00862-w.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1059_CR41","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ekir.2020.05.003","volume":"5","author":"LA Greenbaum","year":"2020","unstructured":"Greenbaum LA, Licht C, Nikolaou V, Al-Dakkak I, Green J, Haas CS, et al. Functional assessment of fatigue and other patient-reported outcomes in patients enrolled in the Global aHUS Registry. Kidney Int Rep. 2020;5(8):1161\u201371. https:\/\/doi.org\/10.1016\/j.ekir.2020.05.003.","journal-title":"Kidney Int Rep."},{"issue":"5","key":"1059_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373\u201384. https:\/\/doi.org\/10.1007\/s40271-015-0118-z.","journal-title":"Patient"},{"issue":"8","key":"1059_CR43","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jval.2020.04.1831","volume":"23","author":"DJ Mott","year":"2020","unstructured":"Mott DJ, Chami N, Tervonen T. Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences. Value Health. 2020;23(8):979\u201384. https:\/\/doi.org\/10.1016\/j.jval.2020.04.1831.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01059-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01059-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01059-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T02:16:51Z","timestamp":1627006611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01059-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01059-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"7 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this study was provided by Alexion Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Peter Chen, Katerina Anokhina, and Yan Wang are employees of, and may own stocks\/options in, Alexion Pharmaceuticals, Inc. Kate Williams, Daniel Aggio, and Andrew J. Lloyd are employees of Acaster Lloyd Consulting Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"All study materials were submitted to the Western Institutional Review Board, a central institutional review board in the USA, for ethical review. The Western Institutional Review Board reviewed the documents and declared the study exempt from ethical review (tracking number: 2597751-44448981).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All participants consented to participation in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants consented to their data being incorporated in the study's findings in an anonymized manner.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All authors contributed to the study conception and design as well as interpretation of the data. The DCE survey was developed by KW and AJL with input from all authors. The analyses were performed by KW, DA, and AJL. All co-authors have revised all manuscript drafts critically and have approved the final version of the manuscript. All co-authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately addressed and resolved.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}}]}}